Better treatment for acute lymphoblastic leukemia in young people

The ALLTogether study is testing a new, personalized treatment approach for children and young adults newly diagnosed with acute lymphoblastic leukemia (ALL). Instead of giving all patients the same treatment, doctors will use your individual disease characteristics and genetic information to create a customized treatment plan. Some patients may receive CAR-T cell therapy (a newer immunotherapy approach) instead of traditional intensive chemotherapy, with the goal of improving survival and reducing long-term side effects.

Although current treatments for ALL work well for many young people (with survival rates above 75%), some patients still die from the disease or from the side effects of treatment itself. This trial aims to find the right balance—treating aggressive cancers intensely enough while sparing patients who might do well with less intensive care from unnecessary harm.